Health-related quality of life across all stages of autosomal dominant polycystic kidney disease.
BACKGROUND
A limited number of studies have assessed health-related quality of life (HRQoL) in autosomal dominant polycystic kidney disease (ADPKD). Results to date have been conflicting and studies have generally focused on patients with later stages of the disease. This study aimed to assess HRQoL in ADPKD across all stages of the disease, from patients with early chronic kidney disease (CKD) to patients with end-stage renal disease.


METHODS
A study involving cross-sectional patient-reported outcomes and retrospective clinical data was undertaken April-December 2014 in Denmark, Finland, Norway and Sweden. Patients were enrolled into four mutually exclusive stages of the disease: CKD stages 1-3; CKD stages 4-5; transplant recipients; and dialysis patients.


RESULTS
Overall HRQoL was generally highest in patients with CKD stages 1-3, followed by transplant recipients, patients with CKD stages 4-5 and patients on dialysis. Progressive disease predominately had an impact on physical health, whereas mental health showed less variation between stages of the disease. A substantial loss in quality of life was observed as patients progressed to CKD stages 4-5.


CONCLUSIONS
Later stages of ADPKD are associated with reduced physical health. The value of early treatment interventions that can delay progression of the disease should be considered.
Quantify Research, Stockholm, Sweden.
Daniel
D
Eriksson
Quantify Research, Stockholm, Sweden.
Linda
L
Karlsson
Quantify Research, Stockholm, Sweden.
Oskar
O
Eklund
Department of Nephrology, Odense University Hospital, Odense C, Denmark.
Hans
H
Dieperink
Division of Nephrology, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland.
Eero
E
Honkanen
Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
Jan
J
Melin
Department of Nephrology, Vestre Viken Hospital Trust, Drammen, Norway.
Kristian
K
Selvig
Otsuka Pharma Scandinavia, Stockholm, Sweden.
Johan
J
Lundberg
D000368:Aged; D003430:Cross-Sectional Studies; D018450:Disease Progression; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016891:Polycystic Kidney, Autosomal Dominant / Q000628:therapy*; D011788:Quality of Life; D006435:Renal Dialysis; D012189:Retrospective Studies
ADPKD; chronic kidney disease; patient-reported outcomes; polycystic kidney disease; quality of life
Lancet. 2007 Apr 14;369(9569):1287-301
17434405
Pharmacoeconomics. 1993 Nov;4(5):353-65
10146874
BMC Nephrol. 2014 Nov 20;15:182
25412767
Qual Life Res. 2014 Mar;23(2):431-42
23975375
Scand J Public Health. 2009 Jul;37(5):459-66
19411320
Health Policy. 1996 Jul;37(1):53-72
10158943
Nephrol Dial Transplant. 2013 Jun;28(6):1472-87
23300259
Nephrol Dial Transplant. 2014 Sep;29 Suppl 4:iv15-25
25165182
Clin J Am Soc Nephrol. 2009 Mar;4(3):560-6
19261830
Am J Kidney Dis. 2014 Feb;63(2):214-26
24183837
Med Care. 1997 Nov;35(11):1095-108
9366889
Nephrol Dial Transplant. 2016 Jul;31(7):1130-40
26268712
Med Care. 1996 Mar;34(3):220-33
8628042
N Engl J Med. 2008 Oct 2;359(14):1477-85
18832246
BMC Nephrol. 2013 Aug 27;14:179
23978051
Nephrol Dial Transplant. 2015 May;30(5):790-800
25637642